Welcome to the Virtual MS Center!
Ask any question you want about Multiple Sclerosis and one of our experts will answer it as soon as possible.
Here is My Question:
Hello, I am a 50-year old diabetic woman who began Tysabri treatment in 2010. For the past few years I've experienced frequent bouts of bacterial vaginosis. Metronidazole gel initially cured my symptoms but, is now ineffective. Do you have any advice or recommendations? My GYN and I would appreciate the insight. Answer: Bacterial vaginosis is very common and both Natalizumab (Tysabri) and Diabetes increase your risk of this common infection. You may or may not be able to prevent this problems from reoccurring but here are some suggestions: You need to create an acidic environment in the vagina to nurture the growth of lactobacillus and other normal bacterial flora that suppresses the growth of yeast and harmful bacteria. You also need to decrease the amount of glucose in your urine; this glucose in the urine feeds the harmful bacteria and yeast in the vagina that upsets the normal balance of bacteria flora. Lastly, you need to keep the area dry, if possible; any problems with urinary accidents, even small amounts, will further increase the risk of infection. How do you do all of this?
It is not at all clear why Natalizumab (Tysabri) is associated with an increased risk of vaginosis but this seems to be a reproducible finding. If your MS is well controlled on Natalizumab (Tysabri), you may consider extending the interval between infusions to every 8 weeks. This may allow for more recovery time. Many individuals who are JC virus antibody positive increase the interval between infusions, because this change in the dosing interval has been shown to dramatically lower the risk of PML. Most MS specialists have not noticed a significant decrease in the efficacy of Natalizumab (Tysabri), when you increase the dosing interval. In fact a clinical trial is planned to prove that increased dose intervals do not alter the effectiveness of Tysabri Revere (Rip) Kinkel MD Professor of Clinical Neurosciences Director of the Multiple Sclerosis Program Clinical Neurosciences Director University of California San Diego Comments are closed.
|
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.
Archives
September 2024
Categories
All
|